TrialInternational journal of hematology2021
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients.
Morio Matsumoto et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it